Copertina

A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xuewen Ma, Gary Borzillo, Martine J. Christine Kothe, Madhu Sanga, Gerald Chu, James G. Greger, Annemie Deiteren, Edward Attiyeh
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Clinical Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
di: Olena Anoshchenko, et al.
Pubblicazione: (2024)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
di: Mathilde Osty, et al.
Pubblicazione: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Pharmacokinetics and Safety of a Single Subcutaneous or Intramuscular Dose of Ketamine in Healthy Horses
di: Ana Rangel, et al.
Pubblicazione: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients
di: Eleanor A. Lisbon, et al.
Pubblicazione: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
di: Shintaro Akiyama, et al.
Pubblicazione: (2025)

Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
di: Teng‐Li Lin, et al.
Pubblicazione: (2026)

Single‐Dose Pharmacokinetics of Intranasal Levetiracetam in Healthy Dogs
di: Jessica L. Wagner, et al.
Pubblicazione: (2026)

Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis
di: Hongmei Duan, et al.
Pubblicazione: (2025)

Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites
di: Asma El‐Zailik, et al.
Pubblicazione: (2024)

Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
di: Tetsuro Ogawa, et al.
Pubblicazione: (2025)

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma
di: Ruben Malmberg, et al.
Pubblicazione: (2025)

Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
di: Pamela Navarro‐Gonzales, et al.
Pubblicazione: (2024)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
Pubblicazione: (2024)

Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease
di: Yan‐ou Yang, et al.
Pubblicazione: (2024)

Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehler–Danlos Syndrome? Authors' Reply
di: Kim W. E. Sweerts, et al.
Pubblicazione: (2025)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
di: Jatinder Kaur Mukker, et al.
Pubblicazione: (2025)

The Single‐Dose Pharmacokinetics of a Compounded Levetiracetam Formulation and Bioequivalence to a Commercial Formulation in Healthy Dogs
di: Aaron M. Paushter, et al.
Pubblicazione: (2024)

Pharmacokinetics and Physiological Effects of a Single Oral Dose of Oxycodone in Healthy Dogs: A Pilot Study
di: Erika Militana, et al.
Pubblicazione: (2025)

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis
di: Fan Huang, et al.
Pubblicazione: (2024)

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment
di: Raj Vuppalanchi, et al.
Pubblicazione: (2024)

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
di: Kenichi Umehara, et al.
Pubblicazione: (2024)

A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers
di: Shruti M. Raja, et al.
Pubblicazione: (2024)

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT ‐ ACS Emulation Using National Health Insurance Claims Data
di: Li‐Wen Huang, et al.
Pubblicazione: (2025)

Pharmacokinetics of Diclazuril in the Plasma and Cerebrospinal Fluid of Healthy Adult Horses After a Single Oral Dose Administered as a Pelleted Topdressing
di: Elizabeth J. Treece, et al.
Pubblicazione: (2026)

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL‐1: Clinical Pharmacology Results
di: Jue Gong, et al.
Pubblicazione: (2025)

First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS‐986308: A Renal Outer Medullary Potassium Channel Inhibitor
di: Sharif I. Soleman, et al.
Pubblicazione: (2024)

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme
di: Chin Hang Yiu, et al.
Pubblicazione: (2026)

Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review
di: Patricia Y. Chu, et al.
Pubblicazione: (2024)

Correction to Beyond MABEL : An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute ( HESI ) Immuno‐Safety Technical Committee ( ITC )
Pubblicazione: (2024)

Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
di: Titia Q. Ruijs, et al.
Pubblicazione: (2024)

Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation Study
di: Amedeo De Nicolò, et al.
Pubblicazione: (2025)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
di: Anupam Kumar Singh, et al.
Pubblicazione: (2025)

Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A ( LY3509754 ): A Phase I Randomized Placebo‐Controlled Study
di: Amita Datta‐Mannan, et al.
Pubblicazione: (2024)

Participants in the FDA's Biomarker Qualification Program
di: Mahnum Shahzad, et al.
Pubblicazione: (2025)

Assessment of Dosing Strategies for Pediatric Drug Products
di: Zachary L. Taylor, et al.
Pubblicazione: (2024)

A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
di: Huy X. Ngo, et al.
Pubblicazione: (2024)

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer
di: Emmanuel Chigutsa, et al.
Pubblicazione: (2026)

Telemetric Assessment and Comparison of Regional Colonic Metabolic Activity in Ambulant Healthy Individuals Using pH and Gas‐Sensing Wireless Motility Capsules
di: Phoebe A. Thwaites, et al.
Pubblicazione: (2025)